✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Liraglutide

Released: Last reviewed:

Daily GLP-1 receptor agonist. Brand names: Victoza (T2D), Saxenda (chronic weight management). Older agent, lower weight loss than semaglutide or tirzepatide.

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Liraglutide overview

Daily GLP-1 receptor agonist. Brand names: Victoza (T2D), Saxenda (chronic weight management). Older agent, lower weight loss than semaglutide or tirzepatide.

Liraglutide at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

Liraglutide is sold as Victoza for type 2 diabetes and Saxenda for weight management. The Saxenda label covers adults and patients 12 and older weighing more than 60 kg with obesity, as a once-daily injection; the Victoza label covers type 2 diabetes from age 10. In the liraglutide adolescent trial (NEJM 2020), 43.3% of teens on liraglutide 3.0 mg cut their BMI by at least 5%, against 18.7% on placebo. FDA drug-shortage data (openFDA) still list liraglutide injection as in shortage, with an update dated October 14, 2026.